Randomization Unethical For VNS Depression Patients, Cyberonics Says
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics says a one-year, 300-patient, non-randomized study should be sufficient to remove placebo effects encountered in its clinical trial evaluating VNS Therapy for depression
You may also be interested in...
FDA’s Second-Guessing Of Device Applications Spurs Public Citizen Protest
Public Citizen cites FDA's vacillations over Cyberonics' VNS Therapy as the source of its concern with the device as a possible treatment for depression
FDA’s Second-Guessing Of Device Applications Spurs Public Citizen Protest
Public Citizen cites FDA's vacillations over Cyberonics' VNS Therapy as the source of its concern with the device as a possible treatment for depression
Cyberonics Resumes Bid For Depression Indication, Submits Two-Year Data
Cyberonics is betting that two-year follow-up data from 240 depression patients treated with VNS Therapy will allay FDA's concerns about inherent trial bias in its non-randomized pivotal study